Results 21 to 30 of about 7,834 (208)
Breast, 2021 Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the perspective ...
Antonio Olry de Labry Lima +8 more
doaj +1 more source
Heliyon, 2023 A rapid, sensitive, and simple UHPLC-MS/MS method for the determination of the PARP inhibitor talazoparib in mouse plasma was developed and validated using [13C,2H4]-talazoparib as an internal standard (IS).
Zahra Talebi +7 more
doaj +1 more source
PLoS ONE, 2022 This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare
Florian Schwarz +3 more
doaj +2 more sources
Frontiers in Oncology, 2022 MUS81 is a critical endonuclease involved in heterodimer formation with Eme1/Mms4 and an important DNA damage repair regulatory molecule. Our previous study suggested that MUS81 was overexpressed and its high expression was positively correlated with ...
Tao Wang +10 more
doaj +1 more source
Frontiers in Oncology, 2021 Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression.
Giacomo Barchiesi +6 more
doaj +1 more source
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer [PDF]
Journal of Personalized Medicine, 2021 The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors.
Florian G. Klein +7 more
openaire +3 more sources
Assessment of the PARP inhibitor talazoparib photosafety profile
Biomedicine & Pharmacotherapy, 2023 Talazoparib (TLZ) is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor employed for the treatment of breast cancer. This drug displays an absorption band in the UVA region, and therefore investigation of the possible phototoxic side-effects associated to its administration results of enormous relevance. In this context, we describe here a
Alejandro Mateos-Pujante +2 more
openaire +3 more sources
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
Scientific Reports, 2022 The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors.
Xia Ding +18 more
doaj +1 more source
Molecules, 2023 The protein PARP1, which plays a crucial role in DNA repair processes, is an attractive target for cancer therapy, especially for BRCA-deficient cancers.
Fengqin Yan +3 more
doaj +1 more source
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]
, 2016 Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide +4 more
core +2 more sources